Related Experiment Video
Updated: Jun 24, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment
Fabiana Perrone1, Francesco Facchinetti2, Benedetta Pellegrino1
1Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Introduction:
Several biomarkers are currently available to address targeted treatments in cancer patients, with lung malignancies representing one of the best examples.
Case Description:
We report the case of a patient affected by advanced non-small cell lung cancer with an uncommon histology and a complex biology. The use of a large next-generation sequencing (NGS) NGS panel allowed us to identify an extremely rare BRAF mutation (V600Q), a MET amplification, a high tumor mutational burden, a germline pathogenetic BRCA1 mutation and a homologous recombination deficiency through RAD51 assay. The treatment decision was driven by the abundance of molecular information.
Conclusions:
This case highlights that an attentive and critical evaluation of molecular reports is key for the tailoring of treatment algorithms at the patient-level scale.
Insights
Advanced non-small cell lung cancer with rare mutations, including BRAF V600Q and BRCA1, was identified using next-generation sequencing. Comprehensive molecular profiling guided personalized treatment decisions for this complex case.
Area of Science:
- Oncology
- Genomics
- Molecular Diagnostics
Background:
- Targeted therapies in lung cancer rely on identifying specific biomarkers.
- Non-small cell lung cancer (NSCLC) presents diverse histological and molecular subtypes.
Observation:
- A patient with advanced NSCLC exhibited uncommon histology and complex molecular features.
- Next-generation sequencing (NGS) identified a rare BRAF V600Q mutation, MET amplification, high tumor mutational burden, and a germline BRCA1 mutation.
Findings:
- Homologous recombination deficiency (HRD) was confirmed via RAD51 assay.
- The patient's molecular profile was highly complex, featuring multiple actionable alterations.
Implications:
- This case underscores the importance of comprehensive molecular profiling in NSCLC.
- Tailoring treatment based on detailed molecular data is crucial for optimizing patient outcomes.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
08:53Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
Published on: February 17, 2011
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:31Homologous Recombination